2024-12-12
2026-09-30
2026-11-30
18
NCT06758544
Guangdong Provincial People's Hospital
Guangdong Provincial People's Hospital
INTERVENTIONAL
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination with Chemotherapy for Resectable Pancreatic Cancer
This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer. The study is planned to enroll 18 subjects. The entire study consists of a screening period of up to 28 days, treatment period, and a follow-up period (safety follow-up 28 days after the final study dose and survival follow-up once every 3 months).
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2025-01-02 | N/A | 2025-01-02 |
2025-01-02 | N/A | 2025-01-03 |
2025-01-03 | N/A | 2024-12 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
Treatment
Allocation:
Na
Interventional Model:
Single Group
Masking:
None
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| EXPERIMENTAL: VRT106 combination with chemotherapy VRT106 combination with chemotherapy | DRUG: Oncolytic virus VRT106
DRUG: Chemotherapy
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Safety and tolerability | Incidence rate of TRAE | About 3 years |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Disease-free survival rate | Disease-free survival rates at 6, 12, 18, and 24 months | About 3 years |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Chen RF Prof. Phone Number: 020-83525210 Email: chenrf63@163.com |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.
Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved
